tariquidar has been researched along with novobiocin in 4 studies
| Studies (tariquidar) | Trials (tariquidar) | Recent Studies (post-2010) (tariquidar) | Studies (novobiocin) | Trials (novobiocin) | Recent Studies (post-2010) (novobiocin) |
|---|---|---|---|---|---|
| 210 | 16 | 138 | 2,271 | 15 | 290 |
| Protein | Taxonomy | tariquidar (IC50) | novobiocin (IC50) |
|---|---|---|---|
| DNA gyrase subunit B | Mycolicibacterium smegmatis MC2 155 | 0.046 | |
| DNA gyrase subunit B | Staphylococcus aureus | 0.0474 | |
| DNA gyrase subunit B | Streptococcus pneumoniae TIGR4 | 0.037 | |
| DNA gyrase subunit A | Escherichia coli K-12 | 0.1441 | |
| DNA gyrase subunit B | Escherichia coli K-12 | 0.1537 | |
| DNA topoisomerase 4 subunit B | Staphylococcus aureus | 7.9 | |
| DNA gyrase subunit B | Mycolicibacterium smegmatis | 0.161 | |
| DNA gyrase subunit A | Staphylococcus aureus | 0.0383 | |
| DNA gyrase subunit B | Mycobacterium tuberculosis H37Rv | 0.0446 | |
| DNA gyrase subunit A | Mycobacterium tuberculosis H37Rv | 0.1315 | |
| DNA topoisomerase | Streptococcus pneumoniae | 2.03 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Müller, H; Pick, A; Wiese, M | 2 |
| Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
| Klinkhammer, W; Pick, A; Wiese, M | 1 |
1 review(s) available for tariquidar and novobiocin
| Article | Year |
|---|---|
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
3 other study(ies) available for tariquidar and novobiocin
| Article | Year |
|---|---|
Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2).
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Humans; Models, Molecular; Molecular Structure; Neoplasm Proteins; Phthalic Acids; Quantitative Structure-Activity Relationship; Quinolines; Reproducibility of Results; Stereoisomerism; Time Factors; Tumor Cells, Cultured | 2008 |
Novel lead for potent inhibitors of breast cancer resistance protein (BCRP).
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Benzimidazoles; Cell Line, Tumor; Chlorophyll; Humans; Molecular Conformation; Neoplasm Proteins; Phenylurea Compounds; Small Molecule Libraries | 2010 |
Specific inhibitors of the breast cancer resistance protein (BCRP).
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Binding Sites; Breast Neoplasms; Cell Line, Tumor; Chlorophyll; Diketopiperazines; Drug Resistance, Multiple; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Imatinib Mesylate; Indoles; Neoplasm Proteins; Novobiocin; Piperazines; Pyrimidines; Quinolines; Structure-Activity Relationship | 2010 |